Profile of sacubitril/valsartan in the treatment of heart failure: patient selection and perspectives

With an estimated prevalence of 5.8 million in the USA and over 23 million people worldwide, heart failure (HF) is growing in epidemic proportions. Despite the use of guideline-directed medical therapies such as angiotensin-converting enzyme inhibitors, beta-adrenergic blockers, angiotensin receptor...

Descripción completa

Detalles Bibliográficos
Autores principales: Yandrapalli, Srikanth, Andries, Gabriela, Biswas, Medha, Khera, Sahil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5634378/
https://www.ncbi.nlm.nih.gov/pubmed/29042791
http://dx.doi.org/10.2147/VHRM.S114784

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5634378/
https://www.ncbi.nlm.nih.gov/pubmed/29042791
http://dx.doi.org/10.2147/VHRM.S114784

Ejemplares similares